Hexarelin Reconstitution Calculator

No. Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide growth hormone secretagogue sold as an unregulated "research compound"; it has no regulatory approval for performance, physique, or any therapeutic indication, and no regulatory-grade RCT exists for athlete use (observational/review). It activates the ghrelin receptor GHS-R1a in the hypothalamus/pituitary, driving endogenous GH release, plus a second receptor, CD36, in heart and vasculature (mechanistic). It is WADA-prohibited; use in tested sport is doping.

Subcutaneous injection is the standard self-administered route (community protocol). Human data across routes exist (human): intravenous 2 µg/kg produces near-maximal GH release, exceeding GHRH; subcutaneous 1.5 µg/kg gives a robust GH pulse; intranasal 20 µg/kg acute and 60 µg/kg three times daily chronic were used clinically in short children,. Oral dosing is not viable: ~0.3% bioavailability because trypsin deamidates the Lys residue (human PK/in-vitro). Community protocols: 100–200 µg SC, 2–3× daily fasted, commonly stacked with a GHRH analogue, since hexarelin+GHRH increases the GH AUC by about 60% versus hexarelin alone (human). Note the GH response correlates inversely with fat mass, higher body fat blunts the pulse, so heavier users typically need relatively larger doses (observational).

Unproven in humans; no RCT addresses recomposition, and the evidence tier for performance indications is low. Animal data are encouraging: continuous hexarelin in obese MC4RKO mice restored pulsatile GH, reduced visceral fat and liver triglycerides, and improved whole-body insulin sensitivity without changing insulin, IGF-1, or glucose tolerance (animal). In insulin-resistant MKR mice, 200 µg/kg twice daily improved glucose/insulin intolerance, lowered plasma and liver triglycerides, decreased fat mass, and increased lean mass (animal). Acute GH release in humans is large and dose-dependent, but chronic GH-axis engagement desensitizes,; treat fat-loss claims as speculative pending human trials.

Hexarelin pulses ACTH, cortisol, and prolactin alongside GH, including during sleep, and reduces slow-wave sleep (human); these rises are dose-dependent. Reported adverse effects in self-administration populations include prolactin/cortisol elevations, appetite changes, dysglycemia, fluid retention, myalgia/arthralgia, and injection-site reactions. However, chronic subcutaneous 1.5 µg/kg twice daily for 16 weeks produced no cumulative HPA overstimulation, cortisol AUC was lower at week 16 than baseline, with no change in prolactin AUC (human). Spillover is real acutely but appears non-cumulative at low chronic doses.

Desensitization is well documented. Short children on intranasal 60 µg/kg t.i.d. lost roughly half their GH response within 7 days, with further blunting at 6–10 months (growth velocity still improved) (human). In rats, repeated 2-h boluses or continuous infusion sharply attenuated GH release, infusions returned GH to baseline within 40 minutes, and IGF-1 rose only after 174 h of continuous exposure (animal). Community consensus: cycle 8–12 weeks at 1–2 doses/day with periodic off-days; expect diminishing returns beyond this (community protocol).

Hexarelin releases more GH than GHRP-6 at equal dose (animal) and more than GHRH in man; unlike GHRH, its effect is only blunted, not abolished, by somatostatin. Its CD36 binding confers cardiovascular tissue actions that GHS-R1a-selective agents lack (mechanistic). The trade-off: broader receptor engagement produces greater cortisol/prolactin spillover than more selective secretagogues; ipamorelin is regarded as the selective, low-spillover option (practitioner consensus). GHRPs synergize with GHRH analogues (human), so common stacks pair hexarelin with CJC-1295 no DAC (community protocol). Choose hexarelin for potency and cardioprotective/neuroprotective goals; ipamorelin for minimal HPA/lactotroph activation (practitioner consensus).

Avoid. No human pregnancy data exist. In mice, hexarelin at 100–200 µg/kg/day decreased ovulation rate, and offspring of treated dams showed impaired memory acquisition, with females more susceptible (animal). Prolactin elevation could theoretically disturb menstrual cyclicity (mechanistic). Discontinue before planned conception in both sexes (practitioner consensus).

Lyophilized hexarelin stores long-term frozen; once reconstituted with bacteriostatic water, refrigerate and use within 2–4 weeks, avoiding repeated freeze-thaw (community protocol). For tested athletes: hexarelin is WADA-prohibited and detectable via competitive serum GHRP assays (human) and validated urine LC-MS/MS. It is metabolized intensively; the hexarelin (1–3) free acid metabolite remains detectable in urine after the parent compound clears, extending the detection window, which varies with individual metabolism, formulation, and route (human).